Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$28.25M+904.51%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Newcomer
- Sector
- Industrials
- Industry
- Specialty Business Services
- Employees
- 226
- Beta
- 0.80
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.65
Financials
Revenue
$28.25M+904.5%Net Income
$6.76M+1306.4%EBITDA
$7.91M+1145.9%Free Cash Flow
$-1.01M-488.0%EPS (diluted)
$0.11+1000.0%Shares Outstanding (diluted)
61.98M+43.7%Operating Expenses
$8.55MCash & Debt
$27.37MReturn of Capital
$199.7KRevenue by Segment (annual)
$82.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $82.03M | $7.55M | $0.14 |
| 2024 | $58.38M | $3.82M | $0.07 |
| 2023 | $47.27M | $6.46M | $0.12 |
| 2022 | $38.03M | $1.03M | $0.02 |
| 2021 | $29.46M | $-2.72M | $-0.05 |
| 2020 | $24.12M | $-9.14M | $-0.19 |
| 2019 | $34.67M | $7.45M | $0.16 |
| 2018 | $23.42M | $2.59M | $0.05 |
| 2017 | $15.23M | $1.79M | $0.04 |
| 2016 | $10.42M | $1.40M | $0.03 |
| 2015 | $8.11M | $-2.41M | $-0.06 |
| 2014 | $10.29M | $2.61M | $0.07 |
| 2013 | $6.31M | $611.7K | $0.02 |
| 2012 | $6.70M | $1.82M | $0.05 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PAYS's reported EPS growth of 8.2% a year over 13 years.
- EPS in 5 years
- $0.21
- Implied price
- $7.61
- Return from $14.23
- -11.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.79 — -73.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 31 | 37 | 43 | 49 |
|---|---|---|---|---|---|
| -1.8% | -26.0% | -22.7% | -19.9% | -17.5% | -15.3% |
| 3.2% | -22.2% | -18.8% | -15.8% | -13.3% | -11.0% |
| 8.2% | -18.4% | -14.8% | -11.8% | -9.1% | -6.7% |
| 13.2% | -14.6% | -10.9% | -7.7% | -4.9% | -2.3% |
| 18.2% | -10.9% | -7.0% | -3.6% | -0.7% | 2.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-33.33%Social Signal Score
Mentions (4)
- Newsmarketbeat.com·39d ago·Neutral
Paysign Targets $117M Revenue as Patient-Affordability Business Surges Paysign NASDAQ: PAYS operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation.
View source ↗ - Newszacks.com·40d ago·Neutral
Paysign (PAYS) is an Incredible Growth Stock: 3 Reasons Why Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - Newszacks.com·40d ago·Positive
Paysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock? Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·56d ago·Positive
3 Reasons Growth Investors Will Love Paysign (PAYS) Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $0.09 per share
Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.11 vs $0.06beat
- Tue, May 12$0.09 vs $0.07beat
- Tue, Mar 24$0.02 vs $0.02beat
- Wed, Nov 12$0.04 vs $0.03beat
- Tue, Aug 5$0.02 vs $0.04miss
- Thu, May 8$0.05 vs $0.02beat
Estimates and results for PAYS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PAYS officers and directors.
- Bought
- —
- Sold
- $8.4m
0 trades
23 trades
- Herman Joan Msold
- Herman Joan Msold
- Ngo Michael Csold
- Ngo Michael Csold
- Baker Jeffery Bradfordsold
- Newcomer Marksold
- Newcomer Marksold
- Herman Joan Msold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PAYS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.